HC Wainwright Has Positive Forecast for LYRA Q3 Earnings

Lyra Therapeutics, Inc. (NASDAQ:LYRA) – Analysts at HC Wainwright lifted their Q3 2025 earnings estimates for shares of Lyra Therapeutics in a research note issued to investors on Thursday, August 14th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($6.52) for the quarter, up from their previous estimate of ($8.87). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Lyra Therapeutics’ current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Lyra Therapeutics’ Q4 2025 earnings at ($7.14) EPS, FY2026 earnings at ($7.02) EPS, FY2027 earnings at ($6.35) EPS, FY2028 earnings at ($4.01) EPS and FY2029 earnings at ($1.33) EPS.

Lyra Therapeutics (NASDAQ:LYRA) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($5.51) EPS for the quarter, topping the consensus estimate of ($5.79) by $0.28. Lyra Therapeutics had a negative net margin of 5,043.64% and a negative return on equity of 404.56%. The company had revenue of $0.29 million during the quarter, compared to the consensus estimate of $0.18 million.

Separately, Wall Street Zen lowered Lyra Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, July 13th.

Lyra Therapeutics Price Performance

Shares of NASDAQ:LYRA opened at $7.05 on Monday. The firm has a fifty day moving average price of $9.22 and a two-hundred day moving average price of $8.38. Lyra Therapeutics has a one year low of $3.81 and a one year high of $37.50. The company has a market cap of $11.56 million, a price-to-earnings ratio of -0.24 and a beta of 0.16.

Hedge Funds Weigh In On Lyra Therapeutics

A number of hedge funds have recently modified their holdings of the company. Bank of America Corp DE increased its position in shares of Lyra Therapeutics by 33.7% in the second quarter. Bank of America Corp DE now owns 28,542 shares of the company’s stock valued at $256,000 after acquiring an additional 7,190 shares during the period. BNP Paribas Financial Markets purchased a new position in shares of Lyra Therapeutics during the fourth quarter valued at about $51,000. Northern Trust Corp increased its position in shares of Lyra Therapeutics by 56.2% during the fourth quarter. Northern Trust Corp now owns 286,310 shares of the company’s stock valued at $59,000 after buying an additional 103,026 shares during the period. Geode Capital Management LLC increased its position in shares of Lyra Therapeutics by 15.3% during the fourth quarter. Geode Capital Management LLC now owns 885,966 shares of the company’s stock valued at $183,000 after buying an additional 117,578 shares during the period. Finally, JPMorgan Chase & Co. increased its position in shares of Lyra Therapeutics by 161.8% during the fourth quarter. JPMorgan Chase & Co. now owns 156,442 shares of the company’s stock valued at $32,000 after buying an additional 96,681 shares during the period. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Lyra Therapeutics Company Profile

Lyra Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.